111 related articles for article (PubMed ID: 12875732)
1. Clinical observation of serum IL-18, IL-10 and sIL-2R levels in patients with chronic hepatitis C pre- and post antiviral treatment.
Jia H; Du J; Zhu S; Ma Y; Cai H
Chin Med J (Engl); 2003 Apr; 116(4):605-8. PubMed ID: 12875732
[TBL] [Abstract][Full Text] [Related]
2. The roles of serum IL-18, IL-10, TNF-alpha and sIL-2R in patients with chronic hepatitis C.
Jia HY; Du J; Zhu SH; Ma YJ; Chen HY; Yang BS; Cai HF
Hepatobiliary Pancreat Dis Int; 2002 Aug; 1(3):378-82. PubMed ID: 14607710
[TBL] [Abstract][Full Text] [Related]
3. Increased soluble IL-2 receptor levels during interferon and ribavirin treatment are associated with a good response in genotype 2a/2b patients with chronic hepatitis C.
Abe S; Narita R; Matsuhashi T; Oto T; Tabaru A; Otsuki M
Eur J Gastroenterol Hepatol; 2008 May; 20(5):373-8. PubMed ID: 18403937
[TBL] [Abstract][Full Text] [Related]
4. Serum concentrations of sIL-2R, IL-6, TGF-beta1, neopterin, and zinc in chronic hepatitis C patients treated with interferon-alpha.
Grüngreiff K; Reinhold D; Ansorge S
Cytokine; 1999 Dec; 11(12):1076-80. PubMed ID: 10623433
[TBL] [Abstract][Full Text] [Related]
5. Serum levels of interleukin-10, interleukin-12 and soluble interleukin-2 receptor in chronic liver disease type C.
Kitaoka S; Shiota G; Kawasaki H
Hepatogastroenterology; 2003; 50(53):1569-74. PubMed ID: 14571788
[TBL] [Abstract][Full Text] [Related]
6. Role of Th1/Th2 cytokines in serum on the pathogenesis of chronic hepatitis C and the outcome of interferon therapy.
Zhang L; Hao CQ; Miao L; Dou XG
Genet Mol Res; 2014 Nov; 13(4):9747-55. PubMed ID: 25501184
[TBL] [Abstract][Full Text] [Related]
7. Serum interleukin 2 and soluble interleukin 2 receptor in chronic active hepatitis C: effect of interferon therapy.
Simsek H; Kadayifci A
J Int Med Res; 1996; 24(3):239-45. PubMed ID: 8725984
[TBL] [Abstract][Full Text] [Related]
8. Prognostic value of the soluble interleukin-2 receptor in chronic hepatitis C treated with interferon-alfa. Multicenter GER-CYT 04 Group.
Naveau S; Balian A; Degos F; Daurat V; Chevret S; Gayno S; Bastie A; Riachi G; Bartolomei-Portal I; Barange K; Moussalli J; Bailly F; Chaumet-Riffaud P; Emilie D
J Hepatol; 1999 Oct; 31(4):612-7. PubMed ID: 10551383
[TBL] [Abstract][Full Text] [Related]
9. Differences between interferon-alpha and -beta treatment for patients with chronic hepatitis C virus infection.
Furusyo N; Hayashi J; Ohmiya M; Sawayama Y; Kawakami Y; Ariyama I; Kinukawa N; Kashiwagi S
Dig Dis Sci; 1999 Mar; 44(3):608-17. PubMed ID: 10080158
[TBL] [Abstract][Full Text] [Related]
10. Bone mineral density and cytokine levels during interferon therapy in children with chronic hepatitis B: does interferon therapy prevent from osteoporosis?
Gur A; Dikici B; Nas K; Bosnak M; Haspolat K; Sarac AJ
BMC Gastroenterol; 2005 Sep; 5():30. PubMed ID: 16171525
[TBL] [Abstract][Full Text] [Related]
11. Increased frequency of interferon-gamma-producing peripheral blood CD4+ T cells in chronic hepatitis C virus infection.
Kawakami Y; Nabeshima S; Furusyo N; Sawayama Y; Hayashi J; Kashiwagi S
Am J Gastroenterol; 2000 Jan; 95(1):227-32. PubMed ID: 10638589
[TBL] [Abstract][Full Text] [Related]
12. Immunomodulators, sFas and Fas-L as potential noninvasive predictors of IFN treatment in patients with HCV genotype-4.
Zekri AR; Haleem HA; Esmat GE; Bahnassy AA; El-Din HM; Hafez MM; Sharaby AF; Sharaf H; Zakaria MS
J Viral Hepat; 2007 Jul; 14(7):468-77. PubMed ID: 17576388
[TBL] [Abstract][Full Text] [Related]
13. Serum soluble interleukin-2 receptor levels before and during interferon treatment in patients with chronic hepatitis B virus infection.
Sawayama Y; Hayashi J; Kawakami Y; Furusyo N; Ariyama I; Kishihara Y; Ueno K; Kashiwagi S
Dig Dis Sci; 1999 Jan; 44(1):163-9. PubMed ID: 9952238
[TBL] [Abstract][Full Text] [Related]
14. [Immune-regulating Th1- and Th2-cytokines in chronic infections caused by hepatitis B and C viruses].
Priĭmiagi LS; Tefanova VT; Tallo TG; Shmidt EV; Solomonova OV; Tuĭsk TP
Vopr Virusol; 2003; 48(4):37-40. PubMed ID: 12945206
[TBL] [Abstract][Full Text] [Related]
15. Up-regulation of IL-18 by interferon alpha-2b/ribavirin combination therapy induces an anti-viral effect in patients with chronic hepatitis C.
Murata K; Yamamoto N; Kawakita T; Saito Y; Yamanaka Y; Sugimoto K; Shiraki K; Nakano T; Tameda Y
Hepatogastroenterology; 2005; 52(62):547-51. PubMed ID: 15816475
[TBL] [Abstract][Full Text] [Related]
16. Impact of Schistosoma mansoni co-infection on serum profile of interferon-gamma, interleukin-4 and interleukin-10 in patients with chronic hepatitis C virus infection.
Emam EA; Emam M; Shehata AE; Emara M
Egypt J Immunol; 2006; 13(2):33-40. PubMed ID: 18689269
[TBL] [Abstract][Full Text] [Related]
17. Effect of alpha 2b interferon on inducement of mIL-2R and treatment of HCV in PBMC from patients with chronic viral hepatitis C.
Wang J; Xiang GJ; Liu BX
World J Gastroenterol; 2003 Apr; 9(4):751-4. PubMed ID: 12679925
[TBL] [Abstract][Full Text] [Related]
18. Lymphoblastoid interferon alfa-n1 improves the long-term response to a 6-month course of treatment in chronic hepatitis C compared with recombinant interferon alfa-2b: results of an international randomized controlled trial. Clinical Advisory Group for the Hepatitis C Comparative Study.
Farrell GC; Bacon BR; Goldin RD
Hepatology; 1998 Apr; 27(4):1121-7. PubMed ID: 9537453
[TBL] [Abstract][Full Text] [Related]
19. Serum cytokine profiles in patients with adult onset Still's disease.
Choi JH; Suh CH; Lee YM; Suh YJ; Lee SK; Kim SS; Nahm DH; Park HS
J Rheumatol; 2003 Nov; 30(11):2422-7. PubMed ID: 14677188
[TBL] [Abstract][Full Text] [Related]
20. Serum levels of interleukin-18 (IL-18) and soluble interleukin-2 receptor (sIL-2R) in lung cancer.
Naumnik W; Chyczewska E; Kovalchuk O; Tałałaj J; Izycki T; Panek B
Rocz Akad Med Bialymst; 2004; 49():246-51. PubMed ID: 15631351
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
